185 related articles for article (PubMed ID: 11927614)
1. Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5.
Nakamura H; Kasuya H; Mullen JT; Yoon SS; Pawlik TM; Chandrasekhar S; Donahue JM; Chiocca EA; Chung RY; Tanabe KK
J Clin Invest; 2002 Apr; 109(7):871-82. PubMed ID: 11927614
[TBL] [Abstract][Full Text] [Related]
2. B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells.
Chung RY; Saeki Y; Chiocca EA
J Virol; 1999 Sep; 73(9):7556-64. PubMed ID: 10438845
[TBL] [Abstract][Full Text] [Related]
3. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene.
Pawlik TM; Nakamura H; Mullen JT; Kasuya H; Yoon SS; Chandrasekhar S; Chiocca EA; Tanabe KK
Cancer; 2002 Sep; 95(5):1171-81. PubMed ID: 12209705
[TBL] [Abstract][Full Text] [Related]
4. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma.
Yoon SS; Nakamura H; Carroll NM; Bode BP; Chiocca EA; Tanabe KK
FASEB J; 2000 Feb; 14(2):301-11. PubMed ID: 10657986
[TBL] [Abstract][Full Text] [Related]
5. Herpes Simplex Virus 1 Mutant with Point Mutations in
Mostafa HH; Thompson TW; Konen AJ; Haenchen SD; Hilliard JG; Macdonald SJ; Morrison LA; Davido DJ
J Virol; 2018 Apr; 92(7):. PubMed ID: 29321311
[TBL] [Abstract][Full Text] [Related]
6. Dephosphorylation of eIF-2alpha mediated by the gamma(1)34.5 protein of herpes simplex virus type 1 is required for viral response to interferon but is not sufficient for efficient viral replication.
Cheng G; Yang K; He B
J Virol; 2003 Sep; 77(18):10154-61. PubMed ID: 12941928
[TBL] [Abstract][Full Text] [Related]
7. AlaArg motif in the carboxyl terminus of the gamma(1)34.5 protein of herpes simplex virus type 1 is required for the formation of a high-molecular-weight complex that dephosphorylates eIF-2alpha.
Cheng G; Gross M; Brett ME; He B
J Virol; 2001 Apr; 75(8):3666-74. PubMed ID: 11264356
[TBL] [Abstract][Full Text] [Related]
8. Second-site mutation outside of the U(S)10-12 domain of Deltagamma(1)34.5 herpes simplex virus 1 recombinant blocks the shutoff of protein synthesis induced by activated protein kinase R and partially restores neurovirulence.
Cassady KA; Gross M; Gillespie GY; Roizman B
J Virol; 2002 Feb; 76(3):942-9. PubMed ID: 11773369
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional viral protein γ34.5 manipulates nucleolar protein NOP53 for optimal viral replication of HSV-1.
Meng W; Han SC; Li CC; Dong HJ; Wang XJ
Cell Death Dis; 2018 Jan; 9(2):103. PubMed ID: 29367603
[TBL] [Abstract][Full Text] [Related]
10. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil.
Nakamura H; Mullen JT; Chandrasekhar S; Pawlik TM; Yoon SS; Tanabe KK
Cancer Res; 2001 Jul; 61(14):5447-52. PubMed ID: 11454690
[TBL] [Abstract][Full Text] [Related]
11. The second-site mutation in the herpes simplex virus recombinants lacking the gamma134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha.
Cassady KA; Gross M; Roizman B
J Virol; 1998 Sep; 72(9):7005-11. PubMed ID: 9696792
[TBL] [Abstract][Full Text] [Related]
12. Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen.
Kasuya H; Pawlik TM; Mullen JT; Donahue JM; Nakamura H; Chandrasekhar S; Kawasaki H; Choi E; Tanabe KK
Cancer Res; 2004 Apr; 64(7):2561-7. PubMed ID: 15059912
[TBL] [Abstract][Full Text] [Related]
13. Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus.
Petrowsky H; Roberts GD; Kooby DA; Burt BM; Bennett JJ; Delman KA; Stanziale SF; Delohery TM; Tong WP; Federoff HJ; Fong Y
J Virol; 2001 Aug; 75(15):7050-8. PubMed ID: 11435585
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy.
Kramm CM; Chase M; Herrlinger U; Jacobs A; Pechan PA; Rainov NG; Sena-Esteves M; Aghi M; Barnett FH; Chiocca EA; Breakefield XO
Hum Gene Ther; 1997 Nov; 8(17):2057-68. PubMed ID: 9414254
[TBL] [Abstract][Full Text] [Related]
15. Herpes simplex virus 1 infection activates the endoplasmic reticulum resident kinase PERK and mediates eIF-2alpha dephosphorylation by the gamma(1)34.5 protein.
Cheng G; Feng Z; He B
J Virol; 2005 Feb; 79(3):1379-88. PubMed ID: 15650164
[TBL] [Abstract][Full Text] [Related]
16. The novel protein kinase of the RR1 subunit of herpes simplex virus has autophosphorylation and transphosphorylation activity that differs in its ATP requirements for HSV-1 and HSV-2.
Peng T; Hunter JR; Nelson JW
Virology; 1996 Feb; 216(1):184-96. PubMed ID: 8614985
[TBL] [Abstract][Full Text] [Related]
17. Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors.
Gayral M; Lulka H; Hanoun N; Biollay C; Sèlves J; Vignolle-Vidoni A; Berthommé H; Trempat P; Epstein AL; Buscail L; Béjot JL; Cordelier P
Hum Gene Ther; 2015 Feb; 26(2):104-13. PubMed ID: 25423447
[TBL] [Abstract][Full Text] [Related]
18. The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase.
He B; Gross M; Roizman B
Proc Natl Acad Sci U S A; 1997 Feb; 94(3):843-8. PubMed ID: 9023344
[TBL] [Abstract][Full Text] [Related]
19. Replication of herpes simplex virus 1 depends on the gamma 134.5 functions that facilitate virus response to interferon and egress in the different stages of productive infection.
Jing X; Cerveny M; Yang K; He B
J Virol; 2004 Jul; 78(14):7653-66. PubMed ID: 15220440
[TBL] [Abstract][Full Text] [Related]
20. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus.
Pawlik TM; Nakamura H; Yoon SS; Mullen JT; Chandrasekhar S; Chiocca EA; Tanabe KK
Cancer Res; 2000 Jun; 60(11):2790-5. PubMed ID: 10850415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
